CN112074522A - 作为用于治疗血小板聚集的蛋白酶激活受体4(par4)抑制剂的化合物 - Google Patents

作为用于治疗血小板聚集的蛋白酶激活受体4(par4)抑制剂的化合物 Download PDF

Info

Publication number
CN112074522A
CN112074522A CN201980030133.4A CN201980030133A CN112074522A CN 112074522 A CN112074522 A CN 112074522A CN 201980030133 A CN201980030133 A CN 201980030133A CN 112074522 A CN112074522 A CN 112074522A
Authority
CN
China
Prior art keywords
mmol
acid
methoxy
reaction
pyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980030133.4A
Other languages
English (en)
Other versions
CN112074522B (zh
Inventor
吴俊军
李硕
温晓明
阳华
魏国平
胡允金
钱苏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen Salubris Pharmaceuticals Co Ltd
Original Assignee
Shenzhen Salubris Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Salubris Pharmaceuticals Co Ltd filed Critical Shenzhen Salubris Pharmaceuticals Co Ltd
Publication of CN112074522A publication Critical patent/CN112074522A/zh
Application granted granted Critical
Publication of CN112074522B publication Critical patent/CN112074522B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明属于化学药物技术领域，特别提供了一系列作为用于治疗血小板聚集的蛋白酶激活受体4(PAR4)抑制剂的化合物及其医药用途。

Description

PCT国内申请，说明书已公开。

Claims (17)

  1. PCT国内申请，权利要求书已公开。
CN201980030133.4A 2018-05-16 2019-05-13 作为用于治疗血小板聚集的蛋白酶激活受体4(par4)抑制剂的化合物 Active CN112074522B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810469296X 2018-05-16
CN201810469296 2018-05-16
PCT/CN2019/086558 WO2019218957A1 (zh) 2018-05-16 2019-05-13 作为用于治疗血小板聚集的蛋白酶激活受体4(par4)抑制剂的化合物

Publications (2)

Publication Number Publication Date
CN112074522A true CN112074522A (zh) 2020-12-11
CN112074522B CN112074522B (zh) 2022-08-26

Family

ID=68539465

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980030133.4A Active CN112074522B (zh) 2018-05-16 2019-05-13 作为用于治疗血小板聚集的蛋白酶激活受体4(par4)抑制剂的化合物

Country Status (2)

Country Link
CN (1) CN112074522B (zh)
WO (1) WO2019218957A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116648244A (zh) * 2021-08-13 2023-08-25 深圳信立泰药业股份有限公司 一种三联吡啶二酮化合物或其盐及其制备方法与应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4265898A (en) * 1978-05-31 1981-05-05 Bayer Aktiengesellschaft Imidazo[2,1-b]-[1,3,4]-thiadiazole compounds, composition and their medicinal use
CN104540835A (zh) * 2012-04-26 2015-04-22 百时美施贵宝公司 用于治疗血小板聚集的作为蛋白酶激活受体4(par4)抑制剂的咪唑并噻二唑衍生物
CN104583218A (zh) * 2012-04-26 2015-04-29 百时美施贵宝公司 作为蛋白酶活化受体4(par4)抑制剂用于治疗血小板聚集的咪唑并噻二唑和咪唑并吡嗪的衍生物
CN104640869A (zh) * 2012-04-26 2015-05-20 百时美施贵宝公司 作为用于治疗血小板聚集的蛋白酶激活受体4(par4)抑制剂的咪唑并噻二唑和咪唑并哒嗪衍生物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4265898A (en) * 1978-05-31 1981-05-05 Bayer Aktiengesellschaft Imidazo[2,1-b]-[1,3,4]-thiadiazole compounds, composition and their medicinal use
CN104540835A (zh) * 2012-04-26 2015-04-22 百时美施贵宝公司 用于治疗血小板聚集的作为蛋白酶激活受体4(par4)抑制剂的咪唑并噻二唑衍生物
CN104583218A (zh) * 2012-04-26 2015-04-29 百时美施贵宝公司 作为蛋白酶活化受体4(par4)抑制剂用于治疗血小板聚集的咪唑并噻二唑和咪唑并吡嗪的衍生物
CN104640869A (zh) * 2012-04-26 2015-05-20 百时美施贵宝公司 作为用于治疗血小板聚集的蛋白酶激活受体4(par4)抑制剂的咪唑并噻二唑和咪唑并哒嗪衍生物

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116648244A (zh) * 2021-08-13 2023-08-25 深圳信立泰药业股份有限公司 一种三联吡啶二酮化合物或其盐及其制备方法与应用
CN116648244B (zh) * 2021-08-13 2023-12-15 深圳信立泰药业股份有限公司 一种三联吡啶二酮化合物或其盐及其制备方法与应用

Also Published As

Publication number Publication date
WO2019218957A1 (zh) 2019-11-21
CN112074522B (zh) 2022-08-26

Similar Documents

Publication Publication Date Title
AU2009205072B2 (en) Condensed aminodihydrothiazine derivative
JP2023506532A (ja) Ｋｒａｓ突然変異型タンパク質阻害剤
KR102494647B1 (ko) 비시클릭 헤테로아릴 치환된 화합물
EP3083589B1 (en) Substituted piperazine compounds and methods of use thereof
AU2016252686B2 (en) 6-membered heterocyclic derivative and pharmaceutical composition comprising same
KR20230006800A (ko) 세포외 단백질의 분해를 위한 asgpr-결합 화합물
TW201512214A (zh) 經取代之核苷類似物之立體選擇性合成方法
CA2800079A1 (en) Macrocyclic compounds as trk kinase inhibitors
KR20140096100A (ko) 이환 피페라진 화합물
KR20190027385A (ko) 비시클릭 헤테로아릴 치환된 화합물
CA3034785C (en) Pde4 inhibitor
CA3183368A1 (en) Tyk-2 inhibitor
CN112074521B (zh) 作为用于治疗血小板聚集的蛋白酶激活受体4(par4)抑制剂的化合物
EP4019521A1 (en) Azaheteroaryl compound and application thereof
CN112074522B (zh) 作为用于治疗血小板聚集的蛋白酶激活受体4(par4)抑制剂的化合物
ES2823127T3 (es) Compuestos tricíclicos de quinolina y azaquinolina sustituidos con heteroarilo como inhibidores de PAR4
WO2016091207A1 (zh) 硝基咪唑类化合物及其制备方法和在制药中的用途
CN112074523B (zh) 作为用于治疗血小板聚集的蛋白酶激活受体4(par4)抑制剂的化合物
TW202337467A (zh) 用於治療疾病之glut9雜環抑制劑

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: Area A, 4th Floor, Digital Peninsula, No. 2, Hongliu Road, Fubao Community, Fubao Street, Futian District, Shenzhen, Guangdong, 518017

Applicant after: SHENZHEN SALUBRIS PHARMACEUTICALS Co.,Ltd.

Address before: 518040 37th floor, chegongmiao Lvjing Plaza, 6009 Shennan Avenue, Futian District, Shenzhen City, Guangdong Province

Applicant before: SHENZHEN SALUBRIS PHARMACEUTICALS Co.,Ltd.

GR01 Patent grant
GR01 Patent grant